TNF Pharma - Volume dana dhuwit perusahaan TNFA

Simbol resmi perusahaan TNF Pharmaceuticals (TNFA)

The cash balance history demonstrates how geopolitical tensions and logistics disruptions are hindering the development of new drugs. The indicator's current value reaches 0.00, driven by strict control over grants and investments aimed at combating age-related pathologies. Unique patents on conjugates and powerful lobbying ensure the stability of TNF Pharmaceuticals (TNFA) positions, creating significant barriers to entry for new players in the sector.

TNFA - Volume dana dhuwit perusahaan tnfpharma.com ing rentang 25.07.2024 - 25.09.2025

Rincian metrik lan analitis perusahaan TNF Pharmaceuticals (TNFA)

- nilai saham lan prakiraan konsensus rega:
Analisis komprehensif perusahaan:TNF Pharmaceuticals
Produk mawa merek TNF Pharma

Developing new drugs requires colossal expenditures from TNF Pharmaceuticals (TNFA), leading to a systematic depletion of reserves. The cash balance trend reflects the market consensus regarding the issuer's current volume of liquid assets. This indicator measures the company's ability to cover operating expenses without external borrowing. While accumulating funds minimizes default risk, excess cash reduces the overall return on equity. The current trend confirms the business's dependence on regular secondary share offerings.

Pesaing TNF Pharmaceuticals

Dana dhuwit perusahaan Haleon (HLN)|Volume dana dhuwit perusahaan Kenvue Inc. (KVUE)|Volume dana dhuwit perusahaan VRNA (veronapharma.com)|Sisa dhuwit perusahaan MENS|LGND: Dhuwit awis perusahaan|Sisa dhuwit perusahaan AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Dhuwit awis perusahaan|Alvotech - Sisa dhuwit perusahaan|Dhuwit awis perusahaan LQDA|Galapagos Genomics (GLPG) - Aset likuid perusahaan|Volume dana dhuwit perusahaan ANIP|Dhuwit awis perusahaan Afrezza MNKD|Dana dhuwit perusahaan Amphastar AMPH|Aset likuid perusahaan Pacira BioSciences (PCRX)|ARS Corp - Volume dana dhuwit perusahaan|TBPH: Dana dhuwit perusahaan|AQST: Volume dana dhuwit perusahaan|SCPH - Aset likuid perusahaan|TECX (Tectonic) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Tonix Pharmaceuticals Holding Corp. TNXP|Dana dhuwit perusahaan SXT Pharmaceuticals (SXTC)|Volume dana dhuwit perusahaan Eupraxia Pharmaceuticals Inc. (EPRX)|Dana dhuwit perusahaan BioHarvest Sciences BHST|EXOZ (Invizyne) - Total volume dana dhuwit perusahaan|ORMP: Dhuwit awis perusahaan|ENTX (Entera Bio Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|HYFT: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan ABVC BioPharma Inc.|CPIX (cumberlandpharma.com) - Volume dana dhuwit perusahaan|Dana dhuwit perusahaan QNTM|Volume dana dhuwit perusahaan FGEN|Dhuwit awis perusahaan Telomir Pharmaceuticals TELO|Volume dana dhuwit perusahaan RANI (ranitherapeutics.com)|SNYR (Synergy CHC Corporation) - Total volume dana dhuwit perusahaan|RLYB - Dana dhuwit perusahaan|LEXX (Lexaria Bioscience Corp.) - Dhuwit awis lan setara dhuwit awis perusahaan|pulmatrix.com (PULM) - Dana dhuwit perusahaan|PTHL (Pheton) - Dana dhuwit perusahaan|Dana dhuwit perusahaan Aptorum|Cadangan dhuwit perusahaan Lyra Therapeutics Inc. LYRA|Volume dana dhuwit perusahaan IBO|YCBD - Cadangan dhuwit perusahaan|PainReform Ltd. - Dhuwit awis perusahaan|CYTO (Auris Medical) - Total volume dana dhuwit perusahaan|LIPO - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OPTN (OptiNose)|PIRS: Volume dana dhuwit perusahaan|Procaps Group S.A. (PROC) - Volume dana dhuwit perusahaan|PTPI (Petros Pharma) - Volume dana dhuwit perusahaan|QLI: Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan SLRN|TFFP (TFF Pharmaceuticals Inc.) - Sisa dhuwit perusahaan